Extra Virgin Olive Oil for Alzheimer's Disease Risk
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment extra virgin olive oil for Alzheimer's disease risk?
Research suggests that extra virgin olive oil, a key part of the Mediterranean diet, may help protect against Alzheimer's disease by improving brain function and reducing harmful protein build-up in the brain. Studies have shown that it can enhance memory and brain connectivity, and lower the risk of cognitive decline.12345
Is extra virgin olive oil safe for human consumption?
How does extra virgin olive oil treatment differ from other Alzheimer's treatments?
What is the purpose of this trial?
Investigators' recent findings from the pilot clinical trial in MCI individuals demonstrated EVOO improved vascular function and memory. Yet, up to date, whether EVOO protects against AD in individuals with a family history of AD is unknown. Thus, in this study, the investigators will recruit healthy individuals with a family history of AD for participation. From eligible participants, blood samples for ApoE genotyping will be collected, followed by metabolomics, lipidomics, and transcriptomics analyses at baseline. Participants will be randomized into 2 groups (n=20 each); one group will receive EVOO daily (\~2 tablespoons, 30 ml) for 6 months, and the second group will not receive olive oil. Both group participants will receive educational information on brain health and how environmental factors such as lifestyle, diet, and exercise could impact brain health. After 6 months, another blood sample will be collected from the participants to evaluate the effect of EVOO on metabolites, lipids, and genes, and thus physiological pathways. The investigators will perform non-targeted and comprehensive metabolomics, lipidomics, and transcriptomics analyses. Examples of metabolites to be analyzed are antioxidative and anti-inflammatory metabolites, neurotransmission, mitochondrial, tryptophan, and purine metabolisms. Examples of lipidomics include sphingomyelins (SMs), cholesterol esters (ChEs), phosphatidylcholines (PCs), phosphatidylethanolamines (PIs), phosphatidylinositols (PIs), and triglycerides (TGs). Transcriptomics will be used to identify changes in mRNAs involved in different pathways contributing to AD, such as genes involved in inflammation and oxidative stress, in both ApoE-dependent and independent fashion.
Eligibility Criteria
This trial is for healthy individuals with a family history of Alzheimer's Disease. Participants should be cognitively normal and not have any neuropsychiatric illnesses like depression or anxiety. Smokers and pregnant women, or those who become pregnant during the study, are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Blood samples collected for ApoE genotyping and baseline metabolomics, lipidomics, and transcriptomics analyses
Treatment
Participants receive daily EVOO or no intervention for 6 months
Follow-up
Blood samples collected to evaluate the effect of EVOO on metabolites, lipids, and genes
Treatment Details
Interventions
- Extra virgin olive oil
Find a Clinic Near You
Who Is Running the Clinical Trial?
Augusta University
Lead Sponsor
Auburn University
Lead Sponsor